WO2016001844A1 - Amorphous form of afatinib dimaleate - Google Patents
Amorphous form of afatinib dimaleate Download PDFInfo
- Publication number
- WO2016001844A1 WO2016001844A1 PCT/IB2015/054919 IB2015054919W WO2016001844A1 WO 2016001844 A1 WO2016001844 A1 WO 2016001844A1 IB 2015054919 W IB2015054919 W IB 2015054919W WO 2016001844 A1 WO2016001844 A1 WO 2016001844A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amorphous form
- reaction mixture
- afatinib dimaleate
- afatinib
- dimaleate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention provides an amorphous form of afatinib dimaleate, processes for its preparation, a pharmaceutical composition comprising it, and its use for the treatment of metastatic non-small cell lung cancer.
- Afatinib dimaleate is a tyrosine kinase inhibitor, chemically designated as 2- butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(35)-tetrahydro-3-furanyl]oxy]-6- quinazolinyl]-4-(dimethylamino)-,(2£)-, (2Z)-2-butenedioate (1:2) having the structure depicted by Formula I.
- 2013/052157 provide processes for the preparation of crystalline forms of afatinib and their salts.
- the present invention provides an amorphous form of afatinib dimaleate, processes for its preparation, a pharmaceutical composition comprising it, and its use for the treatment of metastatic non-small cell lung cancer.
- the amorphous form of afatinib dimaleate is a highly pure, easy to filter, free-flowing solid, and is stable towards polymorphic conversion.
- a first aspect of the present invention provides an amorphous form of afatinib dimaleate.
- a second aspect of the present invention provides a process for the preparation of an amorphous form of afatinib dimaleate comprising:
- a third aspect of the present invention provides a process for the preparation of an amorphous form of afatinib dimaleate comprising:
- a fourth aspect of the present invention provides a process for the preparation of an amorphous form of afatinib dimaleate comprising subjecting a solution of afatinib dimaleate to spray drying, agitated thin film drying, lyophilization, or concentrating a reaction mixture containing afatinib dimaleate in a solvent under reduced pressure.
- a fifth aspect of the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising an amorphous afatinib dimaleate and one or more pharmaceutically acceptable carriers, diluents, or excipients.
- a sixth aspect of the present invention provides the use of an amorphous form of afatinib dimaleate for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have an epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.
- NSCLC metastatic non-small cell lung cancer
- EGFR epidermal growth factor receptor
- Figure 1 X-ray powder diffraction (XRPD) pattern of an amorphous form of afatinib dimaleate.
- ambient temperature refers to a temperature in the range of about 20°C to about 35°C.
- scanning refers to the act of getting solid material (for example, seed crystals) out of a reaction mixture by rubbing or crushing the reaction vessel by any means, for example, through glass rod, spatula, etc.
- Afatinib can be obtained by following the processes disclosed in U.S. Patent No. RE43,431.
- the preparation of the amorphous form of afatinib dimaleate is carried out by reacting afatinib with maleic acid in the presence of one or more solvents and heating the reaction mixture at about 40°C to about 80°C for about 2 hours followed by cooling the reaction mixture to ambient temperature, then scratching the material obtained with a spatula.
- the solvent may be selected from the group comprising alcohols, ketones, alkyl acetates, and mixtures thereof.
- alcohols include methanol, ethanol, n- propanol, isopropanol, «-butanol, and 2-methyl-l-pentanol.
- ketones include acetone, methyl ethyl ketone, and i-butyl ketone.
- alkyl acetates include ethyl acetate, propyl acetate, and /-butyl acetate.
- Isolation of the amorphous form of afatinib dimaleate from its reaction mixture is carried out by concentration, precipitation, cooling, filtration, centrifugation, or a combination thereof, followed by drying. Drying can be carried out using any suitable method, such as drying under reduced pressure, air drying, vacuum tray drying or heating.
- the isolation of the amorphous form of afatinib dimaleate is carried out by filtration, followed by drying at a temperature of about 40°C to about 55°C.
- the amorphous form of afatinib dimaleate can be prepared by subjecting a solution of afatinib dimaleate to spray drying, agitated thin film drying, lyophilization, or concentrating a reaction mixture containing afatinib dimaleate in a solvent under reduced pressure
- amorphous form of afatinib dimaleate of the present invention exhibits an X- ray powder diffraction (XRPD) pattern substantially as depicted in Figure 1.
- the amorphous form of afatinib dimaleate is a highly pure, easy to filter, free- flowing solid, and is stable towards polymorphic conversion.
- X-ray diffraction patterns were recorded using a PANalytical ® X'pert PRO with X'celerator ® as the detector, 0.02 as step size, and 3-40° 2 ⁇ as range, using CuKa radiation.
- the sticky material was scratched with a spatula, and then the reaction mixture was further stirred at about 20°C to about 25°C for about 1 hour.
- the material obtained was filtered, and then washed with ethyl acetate (20 mL).
- the solid obtained was dried under vacuum at about 45°C to about 50°C for about 15 hours to obtain the amorphous form of afatinib dimaleate.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides an amorphous form of afatinib dimaleate, processes for its preparation, a pharmaceutical composition comprising it, and its use for the treatment of metastatic non-small cell lung cancer. The present invention provides an amorphous form of afatinib dimaleate, processes for its preparation, a pharmaceutical composition comprising it, and its use for the treatment of metastatic non-small cell lung cancer. The amorphous form of afatinib dimaleate Is a highly pure, easy to filter, free-flowing solid, and is stable towards polymorphic conversion.
Description
AMORPHOUS FORM OF AFATINIB DIMALEATE
Field of the Invention
The present invention provides an amorphous form of afatinib dimaleate, processes for its preparation, a pharmaceutical composition comprising it, and its use for the treatment of metastatic non-small cell lung cancer.
Background of the Invention
Afatinib dimaleate is a tyrosine kinase inhibitor, chemically designated as 2- butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(35)-tetrahydro-3-furanyl]oxy]-6- quinazolinyl]-4-(dimethylamino)-,(2£)-, (2Z)-2-butenedioate (1:2) having the structure depicted by Formula I.
Formula I
U.S. Patent Nos. RE43,431 and 6,251,912 provide processes for the preparation of afatinib dimaleate.
U.S. Patent No. 8,426,586 and PCT Publication Nos. WO 2012/121764 and WO
2013/052157 provide processes for the preparation of crystalline forms of afatinib and their salts.
Summary of the Invention
The present invention provides an amorphous form of afatinib dimaleate, processes for its preparation, a pharmaceutical composition comprising it, and its use for the treatment of metastatic non-small cell lung cancer. The amorphous form of afatinib
dimaleate is a highly pure, easy to filter, free-flowing solid, and is stable towards polymorphic conversion.
A first aspect of the present invention provides an amorphous form of afatinib dimaleate.
A second aspect of the present invention provides a process for the preparation of an amorphous form of afatinib dimaleate comprising:
i) adding afatinib to maleic acid in the presence of one or more solvents and heating at a temperature of about 40°C to about 80°C to form a reaction mixture;
ii) stirring the reaction mixture;
iii) cooling the reaction mixture; and
iv) isolating the amorphous form of afatinib dimaleate.
A third aspect of the present invention provides a process for the preparation of an amorphous form of afatinib dimaleate comprising:
i) adding afatinib to maleic acid in the presence of one or more solvents and heating at a temperature of about 40°C to about 80°C to form a reaction mixture;
ii) stirring the reaction mixture;
iii) cooling the reaction mixture;
iv) scratching the reaction mixture; and
v) isolating the amorphous form of afatinib dimaleate.
A fourth aspect of the present invention provides a process for the preparation of an amorphous form of afatinib dimaleate comprising subjecting a solution of afatinib dimaleate to spray drying, agitated thin film drying, lyophilization, or concentrating a reaction mixture containing afatinib dimaleate in a solvent under reduced pressure.
A fifth aspect of the present invention provides a pharmaceutical composition comprising an amorphous afatinib dimaleate and one or more pharmaceutically acceptable carriers, diluents, or excipients.
A sixth aspect of the present invention provides the use of an amorphous form of afatinib dimaleate for the first-line treatment of patients with metastatic non-small cell
lung cancer (NSCLC) whose tumors have an epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.
Other objects, features, advantages, and aspects of the present invention will become apparent to those skilled in the art from the description provided herein.
Brief Description of the Drawing
Figure 1 : X-ray powder diffraction (XRPD) pattern of an amorphous form of afatinib dimaleate.
Detailed Description of the Invention
Various embodiments and variants of the present invention are described hereinafter.
The term "about," as used herein, refers to any value which lies within the range defined by a number up to ±10% of the value.
The term "ambient temperature," as used herein, refers to a temperature in the range of about 20°C to about 35°C.
The term "scratching," as used herein, refers to the act of getting solid material (for example, seed crystals) out of a reaction mixture by rubbing or crushing the reaction vessel by any means, for example, through glass rod, spatula, etc.
Afatinib can be obtained by following the processes disclosed in U.S. Patent No. RE43,431.
In an embodiment of the present invention, the preparation of the amorphous form of afatinib dimaleate is carried out by reacting afatinib with maleic acid in the presence of one or more solvents and heating the reaction mixture at about 40°C to about 80°C for about 2 hours followed by cooling the reaction mixture to ambient temperature, then scratching the material obtained with a spatula.
The solvent may be selected from the group comprising alcohols, ketones, alkyl acetates, and mixtures thereof. Examples of alcohols include methanol, ethanol, n- propanol, isopropanol, «-butanol, and 2-methyl-l-pentanol. Examples of ketones include acetone, methyl ethyl ketone, and i-butyl ketone. Examples of alkyl acetates include ethyl acetate, propyl acetate, and /-butyl acetate.
Isolation of the amorphous form of afatinib dimaleate from its reaction mixture is carried out by concentration, precipitation, cooling, filtration, centrifugation, or a combination thereof, followed by drying. Drying can be carried out using any suitable method, such as drying under reduced pressure, air drying, vacuum tray drying or heating.
In an embodiment of the present invention, the isolation of the amorphous form of afatinib dimaleate is carried out by filtration, followed by drying at a temperature of about 40°C to about 55°C.
In another embodiment of the present invention, the amorphous form of afatinib dimaleate can be prepared by subjecting a solution of afatinib dimaleate to spray drying, agitated thin film drying, lyophilization, or concentrating a reaction mixture containing afatinib dimaleate in a solvent under reduced pressure
The amorphous form of afatinib dimaleate of the present invention exhibits an X- ray powder diffraction (XRPD) pattern substantially as depicted in Figure 1.
The amorphous form of afatinib dimaleate is a highly pure, easy to filter, free- flowing solid, and is stable towards polymorphic conversion.
In the foregoing section, embodiments are described by way of an example to illustrate the process of the present invention. However, this is not intended in any way to limit the scope of the present invention. Several variants of the example would be evident to persons ordinarily skilled in the art which are within the scope of the present invention.
Method
X-ray diffraction patterns were recorded using a PANalytical® X'pert PRO with X'celerator® as the detector, 0.02 as step size, and 3-40° 2Θ as range, using CuKa radiation.
Example: Preparation of an amorphous form of afatinib dimaleate
In a round bottom flask, a mixture of afatinib (3 g) and ethyl acetate (30 mL) was heated to about 65°C to obtain a turbid solution. In another round bottom flask, a mixture of maleic acid (1.6 g) and ethyl acetate (30 mL) was heated to about 50°C to obtain a clear solution. The maleic acid solution was added to the afatinib solution, and then the reaction mixture was heated at about 75°C to about 80°C. The reaction mixture was stirred at about 75°C to about 80°C for about 1 hour. The reaction mixture was cooled to about
20°C to obtain a sticky material. The sticky material was scratched with a spatula, and then the reaction mixture was further stirred at about 20°C to about 25°C for about 1 hour. The material obtained was filtered, and then washed with ethyl acetate (20 mL). The solid obtained was dried under vacuum at about 45°C to about 50°C for about 15 hours to obtain the amorphous form of afatinib dimaleate.
Yield: 2.5 g (56%)
Claims
1. An amorphous form of afatinib dimaleate.
2. The amorphous form of afatinib dimaleate according to claim 1, characterized by an X-ray powder diffraction pattern substantially as depicted in Figure 1.
3. A process for the preparation of the amorphous form of afatinib dimaleate of claim 1, comprising:
i) adding afatinib to maleic acid in the presence of one or more solvents and heating at a temperature of about 40°C to about 80°C to form a reaction mixture;
ii) stirring the reaction mixture;
iii) cooling the reaction mixture; and
iv) isolating the amorphous form of afatinib dimaleate.
4. A process for the preparation of the amorphous form of afatinib dimalaete according to claim 1 comprising:
i) adding afatinib to maleic acid in the presence of one or more solvents and heating at a temperature of about 40°C to about 80°C to form a reaction mixture;
ii) stirring the reaction mixture;
iii) cooling the reaction mixture;
iv) scratching the reaction mixture; and
v) isolating the amorphous form of afatinib dimaleate.
5. The process according to claim 3 or claim 4, wherein the solvent is selected from the group comprising alcohols, ketones, alkyl acetates, and mixtures thereof.
6. The process according to claim 3 or claim 4, wherein the solvent is ethyl acetate.7. A process for the preparation of the amorphous form of afatinib dimaleate according to claim 1 comprising subjecting a solution of afatinib dimaleate to spray drying, agitated thin film drying, lyophilization, or concentrating a reaction mixture containing afatinib dimaleate in a solvent under reduced pressure.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1738DE2014 | 2014-06-30 | ||
| IN1738/DEL/2014 | 2014-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2016001844A1 true WO2016001844A1 (en) | 2016-01-07 |
Family
ID=55018527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2015/054919 WO2016001844A1 (en) | 2014-06-30 | 2015-06-30 | Amorphous form of afatinib dimaleate |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2016001844A1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105717226A (en) * | 2016-02-02 | 2016-06-29 | 北京科莱博医药开发有限责任公司 | Method for detecting afatinib dimaleate isomers and main degradation impurities through high performance liquid chromatography |
| WO2018187643A1 (en) | 2017-04-06 | 2018-10-11 | Johnson Matthey Public Limited Company | Novel forms of afatinib dimaleate |
| US10329281B2 (en) * | 2015-04-17 | 2019-06-25 | Hetero Labs Ltd | Polymorphs and process for the preparation of quinazolinyl derivatives |
| WO2020016191A1 (en) * | 2018-07-16 | 2020-01-23 | Universitat Autònoma De Barcelona | Therapeutic use of afatinib in cancer |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040242661A1 (en) * | 2003-03-17 | 2004-12-02 | Igor Rukhman | Polymorphs of valsartan |
| US20070027170A1 (en) * | 2003-10-17 | 2007-02-01 | Rainer Soyka | Process for preparing amino crotonyl compounds |
| WO2012121764A1 (en) * | 2010-11-25 | 2012-09-13 | Ratiopharm Gmbh | Novel salts and polymorphic forms of afatinib |
-
2015
- 2015-06-30 WO PCT/IB2015/054919 patent/WO2016001844A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040242661A1 (en) * | 2003-03-17 | 2004-12-02 | Igor Rukhman | Polymorphs of valsartan |
| US20070027170A1 (en) * | 2003-10-17 | 2007-02-01 | Rainer Soyka | Process for preparing amino crotonyl compounds |
| WO2012121764A1 (en) * | 2010-11-25 | 2012-09-13 | Ratiopharm Gmbh | Novel salts and polymorphic forms of afatinib |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10329281B2 (en) * | 2015-04-17 | 2019-06-25 | Hetero Labs Ltd | Polymorphs and process for the preparation of quinazolinyl derivatives |
| CN105717226A (en) * | 2016-02-02 | 2016-06-29 | 北京科莱博医药开发有限责任公司 | Method for detecting afatinib dimaleate isomers and main degradation impurities through high performance liquid chromatography |
| WO2018187643A1 (en) | 2017-04-06 | 2018-10-11 | Johnson Matthey Public Limited Company | Novel forms of afatinib dimaleate |
| US11136314B2 (en) | 2017-04-06 | 2021-10-05 | Johnson Matthey Public Limited Company | Forms of afatinib dimaleate |
| WO2020016191A1 (en) * | 2018-07-16 | 2020-01-23 | Universitat Autònoma De Barcelona | Therapeutic use of afatinib in cancer |
| US12246016B2 (en) | 2018-07-16 | 2025-03-11 | Universitat Autònoma De Barcelona | Therapeutic use of afatinib in cancer |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101891738B (en) | Dasatinib polymorph and preparation method and medical composition thereof | |
| US10273262B2 (en) | Crystalline form A of obeticholic acid and preparation method thereof | |
| RU2631321C2 (en) | Crystalline form i of tyrosine kinase inhibitor dicaletat and method for its preparation | |
| EP3180343A1 (en) | Solid state forms of ibrutinib | |
| US11390612B2 (en) | Polymorphic forms of Afatinib free base and Afatinib dimaleate | |
| US11072586B2 (en) | Solid state forms of eltrombopag choline | |
| WO2016001844A1 (en) | Amorphous form of afatinib dimaleate | |
| US11084791B2 (en) | Solid state forms of Lenvatinib Mesylate | |
| TW201617347A (en) | Crystal form of hydrogen sulfate of JAK kinase inhibitor and preparation method thereof | |
| WO2016027243A1 (en) | Novel solid state forms of afatinib dimaleate | |
| US10011591B2 (en) | Crystalline form of afatinib dimaleate | |
| CN118302430A (en) | Mono-p-toluene sulfonate and crystal forms of AXL kinase inhibitor | |
| CN112939876A (en) | Crystal form I of Mavacamten and preparation method thereof | |
| CN105859691A (en) | Novel crystal form of thymidine phosphorylase inhibitor and preparation method thereof | |
| CN102428098B (en) | Novel solid substances of { [ (2S,5R,8S,11S) -5-benzyl-11- (3-guanidino-propyl) -8-isopropyl-7-methyl-3, 6,9,12, 15-pentaoxo-1, 4,7,10, 13-pentaaza-cyclopentadecan-2-yl ] -acetic acid } and process for obtaining them | |
| EP4219476A1 (en) | Salt of arylaminoquinazoline-containing compound, and preparation method therefor and use thereof | |
| US20180030038A1 (en) | Polymorphic Forms of Afatinib Dimaleate | |
| US10544142B2 (en) | Crystal forms of palbociclib, and preparation method and use therefor | |
| CA3165784A1 (en) | Salt of arylaminopurine derivative, preparation method therefor and use thereof | |
| CN102190663B (en) | Crystal form of Dimethylamino Arglabin hydrochloride | |
| JP6871255B2 (en) | Method for Producing Crystal Form A of Gefitinib | |
| EP3992173B1 (en) | Treprostinil monohydrate crystals and methods for preparation thereof | |
| CN106957311B (en) | Solvate of raltitrexed and preparation method thereof | |
| CN107629048B (en) | Crystal form of malate of tyrosine kinase inhibitor and preparation method thereof | |
| WO2017093789A1 (en) | Polymorphic forms of afatinib dimaleate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15814837 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 15814837 Country of ref document: EP Kind code of ref document: A1 |